
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : QLS-111
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Canaan Partners
Deal Size : $24.0 million
Deal Type : Series B Financing
Qlaris Bio Completes $24 Million Series B Financing Round To Advance Qls-111
Details : The proceeds will support clinical development of QLS-111, a first-in-class therapeutic that targets episcleral venous pressure to reduce intraocular pressure in glaucoma and ocular hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 30, 2024
Lead Product(s) : QLS-111
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Canaan Partners
Deal Size : $24.0 million
Deal Type : Series B Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : QLS-111,Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Qlaris Bio’s Novel IOP-Lowering Product, QLS-111, is Dosed in Phase II Trials
Details : QLS‑111, a first-in-class therapeutic being developed to lower IOP by targeting episcleral venous pressure in combination wth latanoprost for open angle glaucoma and ocular hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 02, 2024
Lead Product(s) : QLS-111,Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : QLS-111
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients
Details : QLS-111 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glaucoma, Open-Angle.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 08, 2024
Lead Product(s) : QLS-111
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : QLS-111
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : QLS-111 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Low Tension Glaucoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 08, 2023
Lead Product(s) : QLS-111
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : QLS-111
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients
Details : QLS-111 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glaucoma, Open-Angle.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 30, 2023
Lead Product(s) : QLS-111
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : QLS-101
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : QLS-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sturge-Weber Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 10, 2022
Lead Product(s) : QLS-101
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : QLS-101
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study findings demonstrated a favorable safety and tolerability profile for QLS-101, including no evidence of hyperemia (eye redness), as well as a positive efficacy signal, in patients with primary open-angle glaucoma (POAG) or ocular hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 18, 2022
Lead Product(s) : QLS-101
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : QLS-101
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101
Details : QLS-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sturge-Weber Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 01, 2021
Lead Product(s) : QLS-101
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : QLS-101
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate Safety and Tolerability of QLS-101 in NTG
Details : QLS-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Low Tension Glaucoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 23, 2021
Lead Product(s) : QLS-101
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : QLS-101,Timolol Maleate
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101 in Patients with Glaucoma
Details : QLS-101 is a novel adenosine triphosphate (ATP)-sensitive potassium (KATP) channel modulator administered as a topical eyedrop. QLS-101 specifically lowers EVP, a key determinant of IOP, or fluid pressure in the eye, which can be elevated in individuals ...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 15, 2021
Lead Product(s) : QLS-101,Timolol Maleate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
